Tenoforv Response Rate and Adverse Effects in Patients with Chronic Hepatitis B Attending to Hepatitis Clinic at Labbafinejad Hospital

Shahnaz Sali¹ and Maryam Nasiri¹, *

¹Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

*Corresponding author: Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: parvaze100@yahoo.com

Abstract

Background: Tenoforv is one of the therapeutics approved by FDA for treatment of hepatitis B. However, the efficacy of this drug in Iranian patients has not been assessed.

Objectives: Accordingly, the purpose of this study was to determine the effect of tenoforv on DNA and HBe antigen in patients with chronic hepatitis B.

Methods: In this interventional open label trial study, 145 consecutive patients with chronic hepatitis B attending the Hepatitis Clinic at Labbafinejad hospital in Tehran, Iran during years 2016 and 2017, who received tenoforv 300 mg daily, were enrolled with goal-oriented sampling. Data, including age, gender, viral load (DNA), HBe antigen, duration of disease, HBV vaccination history, family history of hepatitis, liver biopsy, risk factors (blood transfusion, having tattoo, history of phlebotomy, having major surgery, being an employee or inmate of prison, unsafe sexual contact, sharing needles and drug injection equipment, having direct contact with blood of an infected person, being a hemodialysis patients, health care workers and others exposed to blood products and needle stick devices, and donor of blood and organs), diagnosis-duration interval, and adverse effects (renal, gastrointestinal, cutaneous, and neurological) were collected by census in 51 patients, who were followed-up to one year using an interview and lab results and the data were recorded and compared.

Results: Mean viral load before and after treatment was $31643426.761 \pm 1553051.267$ IU and $128.08 \pm 434.12$ IU, respectively with a significant difference ($P = 0.001$). The HBe antigen was positive in 7.8% and 2% before and after treatment, respectively, without a significant difference ($P = 0.078$). No adverse effects were seen.

Conclusions: In total, according to the obtained results, it may be concluded that there is good effect for tenoforv on DNA yet not the HBe antigen in patients with chronic hepatitis B. No adverse effects were seen.

Keywords: Effect, Tenofovir, Chronic Hepatitis B

1. Background

Hepatitis is a common infectious disease and an important health issue with increasing trend (1). However, there are differences in prevalence rates worldwide and an increasing rate is seen in the majority of regions (2). Some types of hepatitis B and D subtypes that are transmitted from blood transfusion, shared syringe or sexual route may have chronic status, leading to hepatic dysfunction and cirrhosis (3).

Also, hepatitis patients have higher rate of diabetes, ESRD, obesity, and HIV infection leading to further decrease in their quality of life (4). Since hepatitis has high transmission rate, developing some therapeutic and preventive strategies is important (5), especially for those with blood-transfusion, such as hepatitis B, hepatitis C, HIV1, HIV2, HTLV1, HTLV2, and syphilis (6, 7).

Tenofovir is a therapeutic approved by FDA for treatment of hepatitis B (8-10).

The most commonly reported side effects due to use of tenofovir disoproxil were dizziness, nausea, back pain, skin rash, itching skin, and diarrhea. Long term use of tenofovir is associated with nephrotoxicity and bone loss (11). However, the efficacy of this drug in Iranian patients has not been assessed.

2. Objectives

The purpose of this study was to determine the effect of tenofovir on DNA and HBe antigen in patients with chronic hepatitis B.
3. Methods

In this interventional open-label trial study, 145 consecutive patients with chronic hepatitis B attending a Hepatitis Clinic at Labbafinejad hospital of Tehran, Iran in 2016 and 2017, who received tenofovir 300 mg daily (Tenofovir 300- BAKHTAR BIOSHIMI CO.) were enrolled with goal-oriented sampling. Exclusion criteria were presence of other liver diseases, co-infection with other types of viral hepatitis, HIV infection, organ transplantation, immune deficiency, drug hyper-sensitivity, and patient dissatisfaction.

Data including age, gender, viral load (DNA), HBe antigen, duration of disease, hepatitis B vaccination history, family history of hepatitis, liver biopsy, risk factors (blood transfusion, having tattoo, having major surgery, history of phlebotomy, being an employee or inmate of prison, unsafe sexual contact, sharing needles and drug injection equipment, having direct contact with blood of an infected person, hemodialysis patients, health care workers and others exposed to blood products and needle stick devices, and donor of blood and organs), diagnosis-duration interval, and adverse effects (renal, gastrointestinal, cutaneous, and neurological) were collected by census manner in 51 patients, who were followed-up to one year using interview and lab results and the data were recorded in a checklist.

Data analysis was performed among 51 subjects by SPSS (version 13.0) software (Statistical Procedures for Social Sciences; Chicago, Illinois, USA). Chi-Square, paired- sample-T, and independent-sample-T tests were used and were considered statistically significant at P values less than 0.05.

4. Results

Among 51 patients, the mean age was 47.3 ± 11.9 years. The mean interval between diagnosis and treatment was 4.3 ± 5.6 years. Overall, 44 patients had risk factors for hepatitis B (25 persons (56.8%) had a history of major surgery, nine individuals (20.4%) had history of Phlebotomy, three individuals (6.81%) had history of transfusion, two cases (4.54%) had a tattoo, two cases (4.54%) had a history of sharing needles and drug injection equipment, two (4.54%) were inmate of prisons, and one (2.27%) had unsafe sexual contact. The common diagnostic route was accidental after blood donation. Other demographic data are presented in Table 1.

Mean viral load before and after treatment was 31643426.761 ± 1553051.267 IU and 128.08 ± 434.12 IU respectively with a significant difference (P = 0.001); Table 2. The HBe antigen was positive in 7.8% and 2% before and after treatment, respectively, without a significant difference (P = 0.078). There were no adverse effects

| Table 1. Demographic Data |
|---------------------------|
| Factor | Frequency | Percent |
| Female/male gender | 19/32 | 37.3/62.7 |
| Risk factor | 44 | 86.3 |
| Hepatitis B vaccination history | 7 | 13.7 |
| Family history of hepatitis | 20 | 39.2 |

| Table 2. Viral Load Before and After Treatment |
|---------------------------------------------|
| Mean ± SD |
| Viral load before treatment | 31643426.761 ± 1553051.267 |
| Viral load after treatment | 128.0784 ± 434.1956 |

(renal, gastrointestinal, cutaneous, and neurological). Mean grade and stage were 5.3 and 4.2, respectively, in liver biopsy. Age, gender, hepatitis B vaccination history, family history of hepatitis, liver biopsy, risk factors, and diagnosis-duration interval had no effect on the results.

5. Discussion

The purpose of this study was to determine the effect of tenofovir on DNA and HBe antigen in patients with chronic hepatitis B. The authors found that mean viral load before and after treatment was significantly decreased yet the HBe antigen was not different. The researchers found no case with drug-related adverse effects.

Duarte-Rojo and colleagues (12) reported that in Canada during year 2010, the efficacy of tenofovir in patients with chronic hepatitis B was 93%. However, they reported diarrhea and nausea in 11% and 8%, respectively. However, no adverse effects were seen in the current study. Pan et al. (13) showed that in the United States in 2014 the efficacy of tenofovir in patients with chronic hepatitis B was 79% to 83%. Similarly, they reported no adverse effect.

Also, Lovett et al. in Australia during year 2017, reported that efficacy of tenofovir in patients with chronic hepatitis B is 71% with mild and transient adverse effects (14). However, the results of the current study were better. Ahn et al. in South Korea during year 2017 reported that efficacy of tenofovir in patients with chronic hepatitis B is 80.4% with two severe adverse effects in 209 patients (15). Ke et al. (16) in China during year 2014 reported that efficacy of tenofovir in patients with chronic hepatitis B is 80% with mild and transient adverse effects. The current authors reported no adverse effects.

In total, according to the obtained results, it may be concluded that there is good effect for tenofovir on DNA yet not the HBe antigen in patients with chronic hepatitis B. The limitations of the current study were incomplete data...
that were excluded and also assessment in only one center that decreased the generalization of the results. However, further studies with larger sample sizes and multi-center sampling would develop further evidence with greater reliability and also generalization ability.

Acknowledgments

Correspondent would like to thank her father Dr. Nasiri for his support.

Footnotes

Authors’ Contribution: All authors contributed to all parts of the research.
Conflict of Interests: It is not declared by the authors.
Ethical Approval: This study was approved by the Ethics Committee of the School of Medicine of Shahid Beheshti University of Medical Sciences (code: IR.SBMU.RETECH.REC.1396.847).
Funding/Support: School of Medicine Shahid Beheshti University of Medical Sciences.

References

1. Voiculescu M, Iliescu C, Ionescu C, Micu L, Ismail G, Zilisteanu D, et al. A cross-sectional epidemiological study of HBV, HCV, HDV and HEV prevalence in the Subcarpathian and South-Eastern regions of Romania. J Gastrointestin Liver Dis. 2010;19(1):43-4. [PubMed: 20361074].
2. Bellentani S, Miglioli L, Bedogni G, Croce LS, Tiribelli C. Epidemiology of hepatitis C virus infection. Minerva Gastroenterol Dietol. 2005;31(1):35-29. [PubMed: 15755051].
3. Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP, et al. Acute hepatitis C in a contemporary US cohort: Modes of acquisition and factors influencing viral clearance. J Infect Dis. 2007;196(10):1474-82. doi: 10.1086/522608. [PubMed: 18008226].
4. Basseri B, Yamini D, Chee G, Enayati PD, Tran T, Poordad F. Comorbidities associated with the increasing burden of hepatitis C infection. Liver Int. 2010;30(7):1012-8. doi: 10.1111/j.1478-3231.2010.02235.x. [PubMed: 20408945].
5. [No authors listed]. NIH Consensus Statement on Management of Hepatitis C. 2002. NIH Consen State Sci Statements. 2002;19(3):1-46. [PubMed: 14768714].
6. Scaglione SJ, Lok AS. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology. 2012;142(6):1360-1368. doi: 10.1053/j.gastro.2012.01.044. [PubMed: 22537444].
7. D’Souza R, Foster GR. Diagnosis and treatment of chronic hepatitis B. J R Soc Med. 2004;97(7):38-21. doi: 10.1258/jrsm.97.7.38. [PubMed: 15229255]. [PubMed Central: PMC1079522].
8. Tang CM, Yao TO, Yu J. Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments. World J Gastroenterol. 2014;20(26):6262-78. doi: 10.3748/wjg.v20.i12.6262. [PubMed: 24876747]. [PubMed Central: PMC4033464].
9. Aspinall EJ, Hawkins G, Fraser A, Hutchinson SJ, Goldberg D. Hepatitis B prevention, diagnosis, treatment and care: A review. Occup Med (Lond). 2011;61(8):531-40. doi: 10.1093/occmed/kqr136. [PubMed: 22140489].
10. Jenh AM, Thio CL, Pham PA. Tenofovir for the treatment of hepatitis B virus. Pharmacotherapy. 2009;29(10):1212-27. doi: 10.1592/phco.29.10.1212. [PubMed: 19792994].
11. Ustianowski A, Arends JE. Tenofovir: What we have learnt after 7.5 million person-years of use. Infect Dis Ther. 2015;4(2):445-57. doi: 10.1007/s40121-015-0070-1. [PubMed: 26032649]. [PubMed Central: PMC4470584].
12. Duarte-Rojo A, Heathcote EJ. Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. Therap Adv Gastroenterol. 2010;3(2):207-19. doi: 10.1177/1756283X09354562. [PubMed: 21805955]. [PubMed Central: PMC3002569].
13. Pan CQ, Chan S, Trinh H, Yao A, Bae H, Lou L. Similar efficacy and safety of tenofovir-based therapy in chronic hepatitis B: Australian real world experience. World J Gastroenterol. 2010;16(8):1074-27. doi: 10.3748/wjg.v16.i8.1074. [PubMed: 20587775]. [PubMed Central: PMC4427974].
14. Lovett GC, Nguyen T, Iser DM, Holmes JA, Chen R, Demediuk B, et al. Efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B: World J Gastroenterol. 2015;21(8):5524-31. doi: 10.3748/wjg.v21.i8.5524. [PubMed: 25987775]. [PubMed Central: PMC4427974].
15. Ahn HJ, Song MJ, Jang JW, Bae SH, Choi YJ, Yoon SK. Treatment efficacy and safety of tenofovir-based therapy in chronic hepatitis B: A real life cohort study in Korea. PLoS One. 2017;12(1):e0170362. doi: 10.1371/journal.pone.0170362. [PubMed: 28105258]. [PubMed Central: PMC5526905].
16. Ke W, Liu L, Zhang C, Ye X, Gao Y, Zhou S, et al. Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: A systematic review and meta-analysis. PLoS One. 2014;9(6):e98865. doi: 10.1371/journal.pone.0098865. [PubMed: 24905092]. [PubMed Central: PMC4048232].